Kuros Biosciences (KURN) investor relations material

Strategic direction and commercial expansion

• Opened new U.S. headquarters and manufacturing site in Alpharetta, Georgia, supporting future growth and local production for the U.S. market.

• Achieved significant revenue growth, reaching $146.1 million in 2025, with 72% total growth, $19.6M adjusted EBITDA, $2.6M net profit, and over $19.8 million in cash, becoming profitable with no debt.

• Expanded from spine into foot and ankle, and now trauma, with a methodical approach to market entry, clinical validation, and targeting predictable bone healing after acute injury.

• Building specialized sales and education teams for extremities, investing in clinical trials like the ASTRA study, and deepening engagement with surgeons through education and clinical community development.

• Established strategic alliances, such as with Medtronic, to accelerate market penetration and leverage existing sales channels.

Clinical evidence and innovation

• Invested in multiple Level I clinical trials (MAXA, PROOF, PRECISE, ASTRA) to demonstrate MagnetOs' efficacy, including superiority over autograft in challenging fusion scenarios, with a Level I study showing 79% vs. 47% fusion rates.

• Differentiated by conducting rigorous human studies, histological analyses, and a unique surgical exploration and biopsy initiative, going beyond regulatory requirements.

• Developed and launched innovative products like the MagnetOs MIS Delivery System, with further enhancements and new sizes planned for 2026–2027.

• Pipeline includes settable bone void fillers, antibiotic-eluting formulations, and proprietary Needle Grip technology to stimulate bone growth without added cells or growth factors.

• Ongoing research, customer feedback loops, and new product development initiatives drive future portfolio expansion.

Market positioning and growth outlook

• Gained significant U.S. market share, moving from #9 to #3 in biologics and #2 in fusion products within a year; MagnetOs is now the third largest synthetic bone graft brand by revenue in the U.S.

• Focused on surgeon education, peer-to-peer learning, and building clinical communities to drive adoption, with over 200 surgeons engaged in 2026.

• Addressing large and growing procedure volumes in spine, foot and ankle, and trauma, with tailored commercial strategies and nearly 1 million spine fusion, 600,000 foot & ankle, and over 630,000 trauma procedures annually in the U.S.

• Operational transformation includes dual production footprints, digitalization, and supply chain optimization to support scalability and margin improvement.

• Reconfirmed guidance for 2026, targeting $300–$330 million in revenue and above 20% adjusted EBITDA margin in the midterm.